Business Context and Reporting Period
This Form 8-K is a current report filed by Cara Therapeutics, Inc. on July 16, 2014. The filing addresses Item 5.02 regarding the departure of directors and the appointment of new officers and directors.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Resignations: Ed Hurwitz and Charles Moller, Ph.D., resigned from the Board of Directors on July 16, 2014.
- Appointments: Jeffrey L. Ives, Ph.D., and Harrison M. Bains were appointed as directors on July 16, 2014.
- Committee Assignments: Dr. Ives was appointed to the Audit and Compensation Committees. Mr. Bains was appointed as Chair of the Audit Committee.
- Term Expirations: Dr. Ives's term expires at the 2016 Annual Meeting; Mr. Bains's term expires at the 2015 Annual Meeting.
Guidance, Outlook, and Compensation
The filing details the compensation structure for the new directors under the Company's non-employee director policy:
- Cash Retainers: Both directors receive an annual cash retainer of $35,000 for board service.
- Committee Fees: Mr. Bains receives an additional $13,000 annually for chairing the Audit Committee. Dr. Ives receives an aggregate $11,500 annually for service on the Audit and Compensation Committees.
- Equity: Each director received a stock option for 20,000 shares of common stock on the Effective Date, vesting upon the expiration of their initial term.
- Expenses: The Company will reimburse reasonable out-of-pocket expenses for board meetings.
The filing contains no financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure of director changes.
Investor Verification Checklist
- Verify the professional backgrounds of new directors Jeffrey L. Ives, Ph.D., and Harrison M. Bains to assess their fit for the company's strategic needs.
- Confirm the total number of outstanding stock options following the grant of 40,000 new options (20,000 per director).
- Review the Company's non-employee director compensation policy to ensure the stated retainers align with current market standards.
- Check subsequent filings for any financial impact related to the departure of the previous directors or the integration of the new board members.